Skip to content
Microfluidics Germany Microfluidics China

1 Min Read Time


Microfluidizer® Technology: cGMP Technology for RNA Delivery

The Microfluidics team recently participated in the RNA Therapeutics & Delivery U.S. Congress, in Boston, MA.  This two-day event brought together leading speakers who addressed novel RNA structures, delivery strategies, and cutting-edge presentations on the latest innovations in RNA formulation & clinical development. 

Our team was on hand to learn more about collaborative solutions to RNA therapeutic discovery & modalities and hear about the latest advancements in mRNA vaccines, developing oligo/antisense therapies & exosomes for the advanced delivery of RNA modalities.  

Oxford Global picture

During this  event, Yang Su, Ph.D. (Manager of New Technology and Applications at Microfluidics International Corporation) presented:

Microfluidizer® Technology: A cGMP Technology That Can Help with Scale Up for Both Viral and Non-viral RNA Delivery Platforms 

Interest in RNA-based therapeutics and vaccines has surged in recent years.  However, despite their numerous advantages and therapeutic efficacies, challenges remain in delivering RNAs safely and effectively.

Yangs Presentation at Oxford Global

Dr. Yang Su discussed how viral and lipid-based nanoparticle non-viral vectors are proven successful delivery platforms and Microfluidizer® technology is a scalable technology that can be used in manufacturing both delivery systems.

Microfluidizer® processors have proven superior, replicated nanotechnology results. Microfluidizer® lipid nanoparticles technology is simple to use, achieves consistent particle sizes with narrow distributions, which increases product stability and improves downstream processes such as sterilization - both crucial for lab, pilot, and full-scale vaccine production.

Topics of this discussion included:

  • Drug delivering nanoparticles and challenges during development and manufacturing.
  • Overall benefits of Microfluidizer® technology for addressing nanotechnology applications.
  • Microfluidizer® technology's role in achieving repeatable, scalable results - batch-to-batch and from lab to pilot to production volumes.

You can view a recording of the presentation below:


Drug Delivery Resources

View our Resource Centre to learn more about the development and production of drug delivery using Liposomes, Lipid Nanoparticles, and Nanoparticle Albumin Bound Paclitaxel.

Download the Microfluidics Brochure
Posted by Matt Baumber


Blog articles direct to your inbox




Request a call back or email response

For more information, please contact our team via the form below and a representative will contact you to answer any questions. Phone inquiries can also be made +1-519-884-9660.


Since 2011, Microfluidics has been a member of the IDEX Corporation family of companies. IDEX is a global leader in highly engineered systems and components.

About us